Organisation paid for research Program year 2025 Source: CMS Open Payments

American Oncology Network LLC

Neither a doctor nor a teaching hospital

Research payments

$56,167

48 payments

Through program year 2025, American Oncology Network LLC is reported as receiving $56,167 in research payments, across 48 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$2,326	3
2024	Research	$5,700	8
2021	Research	$48,141	37

Breakdown

Who paid Research payments · program years 2021–2025

AbbVie, Inc. $47,767 22 payments
Pfizer Inc. $5,700 8 payments
Pharmacyclics LLC, An AbbVie Company $2,700 18 payments

Studies the money was for Research payments · program years 2021–2025

Randomized, Double-Blind, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) $33,086 18 payments
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma $12,355 1 payment
An Openlabel Phase 2 Basket Study of Seacd40 Combination Therapies in Advanced Malignancies $5,700 8 payments
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) $2,700 18 payments
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple Myeloma $2,100 1 payment
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting $144 1 payment
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE-FL-2) $82 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.